Fradin M S, Ellis C N, Voorhees J J
Department of Dermatology, University of Michigan Medical Center, Ann Arbor 48109-0314.
Br J Dermatol. 1990 Jun;122 Suppl 36:21-5. doi: 10.1111/j.1365-2133.1990.tb02878.x.
Since its discovery in 1972, cyclosporin A (CyA) has been widely used in the experimental treatment of multiple inflammatory diseases considered to be of immune-mediated aetiology. In dermatology, oral CyA is most effective in the treatment of psoriasis and has been used successfully for plaque-type, pustular and erythrodermic forms of the disease. While dosages ranging from 1 to 14 mg/kg/day have been used, a starting dose of 4 mg/kg/day gives a rapid response with few side-effects. Nephrotoxicity remains the greatest concern in long-term use of the drug. Although intralesional CyA has proven effective in psoriasis, topical preparations have not. It is hoped that future research will provide effective topical formulations of CyA which are efficacious without the risks inherent in systemic administration.
自1972年被发现以来，环孢素A（CyA）已被广泛用于多种被认为由免疫介导病因引起的炎症性疾病的实验性治疗。在皮肤病学中，口服环孢素A对银屑病的治疗最为有效，并已成功用于治疗斑块型、脓疱型和红皮病型银屑病。虽然使用的剂量范围为1至14毫克/千克/天，但起始剂量为4毫克/千克/天能产生快速反应且副作用较少。肾毒性仍然是长期使用该药物时最令人担忧的问题。尽管病灶内注射环孢素A已被证明对银屑病有效，但局部制剂却并非如此。希望未来的研究能够提供有效的环孢素A局部制剂，既能有效治疗又没有全身给药所固有的风险。
